Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of Trastuzumab (Herceptin®)

Strengths and weaknesses of the evidence

The randomised trials discussed in this guideline are large, well designed, and well conducted. Information about long-term results on overall survival and adverse effects for both metastatic breast cancer and early breast cancer is not yet available. These clinical practice recommendations developed by the NBCC* will be reviewed as additional significant evidence becomes available and revised as required.

* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Published using CeCC Docbook Manager